Innovations & Thérapeutiques en Oncologie


Colorectal cancer: from molecular to clinical consensus? Volume 6, issue 1, January-February 2020


  • Figure 1
1 Centre de recherche des Cordeliers INSERM, Sorbonne Université, Université de Paris
Personalized Medicine, Pharmacogenomics, Therapeutic OPtimization (MEPPOT) Team
15, rue de l’École de médecine
F-75006 Paris
2 Hôpital Européen Georges Pompidou Pôle de biologie
20, rue Leblanc
75015 Paris
* Tirés à part

Colorectal cancer (CRC) was one of the first cancers to be characterized from a molecular point of view. Initially divided into three molecular groups (chromosomal instability, microsatellite instability and methylator phenotype), CRC are now classified under four robust subtypes according to a consensual transcription-based molecular classification (“Consensus Molecular Subtypes”, CMS). These groups are firmly linked to biological, genomic and epigenetic characteristics, as well as survival rates. The CMS classification of CRC represents a major advance in our understanding of the molecular mechanisms behind the malignant transformation of colonic epithelial cells, and opens the way for development of a precision-based approach for this cancer.